Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

5318 - Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival


09 Sep 2017


CNS tumours


Translational Research;  Central Nervous System Malignancies


Basak Oyan


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


B. Oyan1, S. Eren2, O. Sonmez1, F. Ozkan3, K. Yaltırak4, U. Ture4

Author affiliations

  • 1 Medical Oncology, Acibadem University School of Medicine, 34662 - Istanbul/TR
  • 2 Internal Medicine, Yeditepe University Hospital, 34752 - Istanbul/TR
  • 3 Pathology, Yeditepe University Hospital, 34752 - Istanbul/TR
  • 4 Neurosurgery, Yeditepe University Hospital, 34752 - Istanbul/TR


Abstract 5318


Although immunotherapy is not an established treatment option in high grade glial tumors, trials are ongoing. One of the main predictive factor for response to immune checkpoint inhibitors is PD-L1 expression status and this can change over time with the effect of therapies like chemotherapy and radiotherapy. The aim of this study is to determine whether PD-L1 expression status changes in recurrent gliomas after chemoradiotherapy and the impact of this change on survival.


PD-L1 expression of 29 patients was evaluated by an expert pathologist with immunohistochemistry. PD-L1 positivity was defined as expression in ≥ 1% of tumor cells. Change in PD-L1 expression status was defined as an absolute 5% difference between two resections.


Of the 29 patients, 15 patients (51.7%) had PD-L1 expression in ≥ 1% of tumor cells and 7 patients (24.1%) had PD-L1 expression in ≥ 10% of tumor cells at diagnosis. Median survival of patients with baseline PD-L1


The PD-L1expression status changes in more than 40% of high grade glial tumors at recurrence after receiving chemotherapy and radiotherapy. So immune responsiveness of glial tumors can be modified by treatments. As the patients in this study did not receive immunotherapy after recurrence, the change in PD-L1 expression probably did not affect survival.

Clinical trial identification

Legal entity responsible for the study

Basak Oyan, Seyma Eren, Ozlem Sonmez


Yeditepe University Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.